EMA's Action Plan To Support ATMPs Expected In Jan 2017
Executive Summary
The European Medicines Agency's action plan to support the development of advanced therapy medicinal products will prioritize on actions that are feasible, will result in major gains without the need for a lot of effort and will not require legislative changes.
You may also be interested in...
EMA Identifies Steps To Foster ATMP Development
EU biotech companies have welcomed the various initiatives that the European Medicines Agency has listed to support the development of advanced therapy medicinal products. However, they want clear timelines on completing these initiatives since their implementation will not require any changes to the current legislative framework.
Gene Therapy Trials In EU Delayed By Environmental Considerations
Pharmaceutical companies in the EU are becoming keener to experiment with genetically-modified advanced therapy medicinal products in patients, but they are finding it hard to navigate through the maze of environmental risk assessment procedures in each member state.
EMA Guidance On Investigational ATMPs To Focus On Exploratory And Pivotal Trials
The European Medicines Agency believes that advanced therapy medicinal product makers need better guidance on differentiating between exploratory and pivotal trials.